Logo image of PBH

PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Price, Forecast & Analysis

USA - NYSE:PBH - US74112D1019 - Common Stock

59.95 USD
-1.41 (-2.3%)
Last: 11/7/2025, 8:07:04 PM
59.95 USD
0 (0%)
After Hours: 11/7/2025, 8:07:04 PM

PBH Key Statistics, Chart & Performance

Key Statistics
Market Cap2.95B
Revenue(TTM)1.14B
Net Income(TTM)213.00M
Shares49.21M
Float48.58M
52 Week High90.04
52 Week Low59.51
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)4.56
PE13.15
Fwd PE12.43
Earnings (Next)02-04 2026-02-04/bmo
IPO2005-02-10
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


PBH short term performance overview.The bars show the price performance of PBH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

PBH long term performance overview.The bars show the price performance of PBH in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -5 -10 -15 -20 -25

The current stock price of PBH is 59.95 USD. In the past month the price decreased by -1.72%. In the past year, price decreased by -25.41%.

PRESTIGE CONSUMER HEALTHCARE / PBH Daily stock chart

PBH Latest News, Press Relases and Analysis

PBH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO42.04874.88B
JNJ JOHNSON & JOHNSON17.97449.32B
MRK MERCK & CO. INC.9.79215.51B
PFE PFIZER INC7.63138.90B
BMY BRISTOL-MYERS SQUIBB CO7.1295.03B
ZTS ZOETIS INC18.9753.29B
RPRX ROYALTY PHARMA PLC- CL A9.3822.49B
VTRS VIATRIS INC4.3411.80B
ELAN ELANCO ANIMAL HEALTH INC22.3910.68B
CORT CORCEPT THERAPEUTICS INC83.777.77B
AXSM AXSOME THERAPEUTICS INCN/A6.89B
LGND LIGAND PHARMACEUTICALS27.783.97B

About PBH

Company Profile

PBH logo image Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

Company Info

PRESTIGE CONSUMER HEALTHCARE

660 White Plains Rd.

Tarrytown NEW YORK 10591 US

CEO: Ronald M. Lombardi

Employees: 570

PBH Company Website

PBH Investor Relations

Phone: 19145246800

PRESTIGE CONSUMER HEALTHCARE / PBH FAQ

What does PRESTIGE CONSUMER HEALTHCARE do?

Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. The company is headquartered in Tarrytown, New York and currently employs 600 full-time employees. The company went IPO on 2005-02-10. The firm is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.


What is the current price of PBH stock?

The current stock price of PBH is 59.95 USD. The price decreased by -2.3% in the last trading session.


Does PRESTIGE CONSUMER HEALTHCARE pay dividends?

PBH does not pay a dividend.


What is the ChartMill technical and fundamental rating of PBH stock?

PBH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Would investing in PRESTIGE CONSUMER HEALTHCARE be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PBH.


What is the next earnings date for PBH stock?

PRESTIGE CONSUMER HEALTHCARE (PBH) will report earnings on 2026-02-04, before the market open.


Who owns PRESTIGE CONSUMER HEALTHCARE?

You can find the ownership structure of PRESTIGE CONSUMER HEALTHCARE (PBH) on the Ownership tab.


PBH Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

PBH Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PBH. Both the health and profitability get an excellent rating, making PBH a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PBH Financial Highlights

Over the last trailing twelve months PBH reported a non-GAAP Earnings per Share(EPS) of 4.56. The EPS increased by 13.15% compared to the year before.


Industry RankSector Rank
PM (TTM) 19.02%
ROA 6.21%
ROE 11.48%
Debt/Equity 0.55
Chartmill High Growth Momentum
EPS Q2Q%-1.83%
Sales Q2Q%-3.41%
EPS 1Y (TTM)13.15%
Revenue 1Y (TTM)1.1%

PBH Forecast & Estimates

10 analysts have analysed PBH and the average price target is 82.42 USD. This implies a price increase of 37.47% is expected in the next year compared to the current price of 59.95.

For the next year, analysts expect an EPS growth of 0.67% and a revenue growth -2.36% for PBH


Analysts
Analysts84
Price Target82.42 (37.48%)
EPS Next Y0.67%
Revenue Next Year-2.36%

PBH Ownership

Ownership
Inst Owners107.07%
Ins Owners1.29%
Short Float %3.39%
Short Ratio3.21